Epilepsy - Pipeline Review, H2 2015

Published: November 2015
No. of Pages: 372
   

Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H2 2015’, provides an overview of the Epilepsy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epilepsy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Epilepsy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Epilepsy - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Epilepsy Overview 12
Therapeutics Development 13
Pipeline Products for Epilepsy - Overview 13
Pipeline Products for Epilepsy - Comparative Analysis 14
Epilepsy - Therapeutics under Development by Companies 15
Epilepsy - Therapeutics under Investigation by Universities/Institutes 21
Epilepsy - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Epilepsy - Products under Development by Companies 27
Epilepsy - Products under Investigation by Universities/Institutes 36
Epilepsy - Companies Involved in Therapeutics Development 38
Acorda Therapeutics, Inc. 38
Advicenne Pharma 39
Aeolus Pharmaceuticals, Inc. 40
Aequus Pharmaceuticals Inc. 41
Aestus Therapeutics, Inc. 42
Alexza Pharmaceuticals, Inc. 43
Allergan Plc 44
Anavex Life Sciences Corp. 45
Asklepios BioPharmaceutical, Inc. 46
Astellas Pharma Inc. 47
Bial - Portela & Ca, S.A. 48
BioCrea GmbH 49
Bionomics Limited 50
Biovista Inc. 51
Biscayne Pharmaceuticals, Inc. 52
Catalyst Pharmaceutical Partners, Inc. 53
Chong Kun Dang Pharmaceutical Corp. 54
Concert Pharmaceuticals, Inc. 55
Convergence Pharmaceuticals Ltd. 56
D-Pharm Ltd. 57
Eisai Co., Ltd. 58
Epirus Biopharmaceuticals, Inc. 59
Glialogix, Inc. 60
GW Pharmaceuticals Plc 61
H. Lundbeck A/S 62
Hyundai Pharmaceutical Co., Ltd. 63
INSYS Therapeutics, Inc. 64
Iproteos S.L. 65
Knopp Biosciences LLC 66
Ligand Pharmaceuticals, Inc. 67
Lipicard Technologies Limited 68
Lohocla Research Corporation 69
Mapi Pharma Ltd. 70
Marathon Pharmaceuticals, LLC 71
Marinus Pharmaceuticals, Inc. 72
MedGenesis Therapeutix Inc. 73
Neurocrine Biosciences, Inc. 74
Neuron Biopharma SA 75
Novartis AG 76
OPKO Health, Inc. 77
PharmatrophiX, Inc. 78
Promius Pharma, LLC 79
Retrophin Inc. 80
Sage Therapeutics 81
Saniona AB 82
SciFluor Life Sciences, LLC 83
SK Biopharmaceuticals Co., Ltd. 84
Sumitomo Dainippon Pharma Co., Ltd. 85
Takeda Pharmaceutical Company Limited 86
Turing Pharmaceuticals AG 87
UCB S.A. 88
Ultragenyx Pharmaceutical Inc. 89
Upsher-Smith Laboratories, Inc. 90
Vichem Chemie Research Ltd. 91
VistaGen Therapeutics , Inc. 92
Xenon Pharmaceuticals Inc. 93
XERIS Pharmaceuticals, Inc. 94
Zogenix, Inc. 95
Zynerba Pharmaceuticals, Inc. 96
Epilepsy - Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Target 98
Assessment by Mechanism of Action 103
Assessment by Route of Administration 107
Assessment by Molecule Type 109
Drug Profiles 111
2-DG - Drug Profile 111
ADV-6208 - Drug Profile 113
ADV-6770 - Drug Profile 114
AEOL-1114B - Drug Profile 115
AEOL-11203 - Drug Profile 116
AEOL-11207 - Drug Profile 117
alprazolam - Drug Profile 118
AMPX-0079 - Drug Profile 120
ANAVEX-273 - Drug Profile 121
AV-101 - Drug Profile 122
AVL-5189 - Drug Profile 124
BIS-001 - Drug Profile 125
BNP-TLE - Drug Profile 126
BPS-015 SR - Drug Profile 127
brivaracetam - Drug Profile 128
BVA-601 - Drug Profile 130
Cannabidiol - Drug Profile 131
carbamazepine - Drug Profile 133
CCG-63802 - Drug Profile 134
Cell Therapy for Central Nervous System Disorders - Drug Profile 135
CHEC-9 - Drug Profile 137
CKD-903 - Drug Profile 139
clobazam - Drug Profile 140
clobazam - Drug Profile 141
CNV-1061436 - Drug Profile 142
cosyntropin - Drug Profile 143
CPP-115 - Drug Profile 144
CTP-354 - Drug Profile 146
CUR-1916 - Drug Profile 147
diazepam - Drug Profile 148
diazepam - Drug Profile 149
diazepam XeriJect - Drug Profile 151
DP-VPA - Drug Profile 152
Drug for Epilepsy - Drug Profile 154
Drug to Agonize GABA Receptor for Epilepsy - Drug Profile 155
Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders - Drug Profile 156
Epidiolex - Drug Profile 157
eslicarbazepine acetate - Drug Profile 159
everolimus - Drug Profile 163
fenfluramine hydrochloride - Drug Profile 169
fosphenytoin sodium - Drug Profile 170
FV-082 - Drug Profile 171
FV-137 - Drug Profile 172
ganaxolone - Drug Profile 173
Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile 175
GLX-1112 - Drug Profile 176
GWP-42006 - Drug Profile 177
IPR-003 - Drug Profile 179
IPR-131 - Drug Profile 180
IPR-96 - Drug Profile 181
KM-113 - Drug Profile 182
KM-314 - Drug Profile 183
lacosamide - Drug Profile 184
lamotrigine - Drug Profile 189
levetiracetam - Drug Profile 190
liatermin - Drug Profile 193
LSPGR-1 - Drug Profile 195
LT-4121 - Drug Profile 196
LT-4122 - Drug Profile 197
LT-4123 - Drug Profile 198
LT-4124 - Drug Profile 199
LT-4125 - Drug Profile 200
LT-4126 - Drug Profile 201
magnesium valproate hydrate - Drug Profile 202
MB-003 - Drug Profile 203
midazolam hydrochloride - Drug Profile 204
MP-101 - Drug Profile 205
MP-102 - Drug Profile 206
MRS-5474 - Drug Profile 207
naluzotan hydrochloride - Drug Profile 208
NB-23R1 - Drug Profile 209
NGT-168 - Drug Profile 210
NH-34 - Drug Profile 211
NRP-2945 - Drug Profile 212
NST-0037 - Drug Profile 214
NST-0076 - Drug Profile 215
Oligonucleotide for Dravet Syndrome - Drug Profile 216
perampanel - Drug Profile 217
pregabalin ER - Drug Profile 220
propofol hemisuccinate - Drug Profile 221
SAGE-217 - Drug Profile 222
SAGE-689 - Drug Profile 223
SCT-66 - Drug Profile 224
selurampanel - Drug Profile 225
sepranolone - Drug Profile 226
SF-0034 - Drug Profile 229
simvastatin - Drug Profile 230
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 231
Small Molecule 2 for Epilepsy - Drug Profile 232
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 233
Small Molecule 3 for Epilepsy - Drug Profile 234
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 235
Small Molecule 4 for Epilepsy - Drug Profile 236
Small Molecule for Epilepsy - Drug Profile 237
Small Molecule for Epilepsy - Drug Profile 238
Small Molecule for Epilepsy - Drug Profile 239
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile 240
Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy - Drug Profile 241
Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile 242
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS - Drug Profile 243
Small Molecule to Inhibit ACHE for Epilepsy - Drug Profile 245
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 246
Small Molecules 1 for Epilepsy - Drug Profile 247
Small Molecules 2 for Epilepsy - Drug Profile 248
Small Molecules 3 for Epilepsy - Drug Profile 249
Small Molecules 4 for Epilepsy - Drug Profile 250
Small Molecules for CNS Disorders - Drug Profile 251
Small Molecules for Epilepsy - Drug Profile 252
Small Molecules for Epilepsy and Neuropathic Pain - Drug Profile 253
Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile 254
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 255
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 256
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 257
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 258
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 259
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 260
Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile 261
Small Molecules to Inhibit Nav1.6 for Dravet Syndrome - Drug Profile 262
Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile 263
sulthiame - Drug Profile 264
TAK-935 - Drug Profile 265
TF-0081 - Drug Profile 266
TG-4155 - Drug Profile 267
topiramate - Drug Profile 268
TPN-102 - Drug Profile 269
TUR-004 - Drug Profile 270
UCB-0942 - Drug Profile 271
UX-007 - Drug Profile 272
VAD-1 - Drug Profile 274
VAD-2 - Drug Profile 275
VB-3323 - Drug Profile 276
VID-45110 - Drug Profile 277
VU-0456810 - Drug Profile 278
YKP-3089 - Drug Profile 279
Z-944 - Drug Profile 281
ZYN-002 - Drug Profile 282
Epilepsy - Recent Pipeline Updates 283
Epilepsy - Dormant Projects 345
Epilepsy - Discontinued Products 352
Epilepsy - Product Development Milestones 354
Featured News & Press Releases 354
Appendix 362
Methodology 362
Coverage 362
Secondary Research 362
Primary Research 362
Expert Panel Validation 362
Contact Us 362
Disclaimer 363

List of Tables

Number of Products under Development for Epilepsy, H2 2015 22
Number of Products under Development for Epilepsy - Comparative Analysis, H2 2015 23
Number of Products under Development by Companies, H2 2015 25
Number of Products under Development by Companies, H2 2015 (Contd..1) 26
Number of Products under Development by Companies, H2 2015 (Contd..2) 27
Number of Products under Development by Companies, H2 2015 (Contd..3) 28
Number of Products under Development by Companies, H2 2015 (Contd..4) 29
Number of Products under Investigation by Universities/Institutes, H2 2015 31
Comparative Analysis by Late Stage Development, H2 2015 32
Comparative Analysis by Clinical Stage Development, H2 2015 33
Comparative Analysis by Early Stage Development, H2 2015 34
Comparative Analysis by Unknown Stage Development, H2 2015 35
Products under Development by Companies, H2 2015 36
Products under Development by Companies, H2 2015 (Contd..1) 37
Products under Development by Companies, H2 2015 (Contd..2) 38
Products under Development by Companies, H2 2015 (Contd..3) 39
Products under Development by Companies, H2 2015 (Contd..4) 40
Products under Development by Companies, H2 2015 (Contd..5) 41
Products under Development by Companies, H2 2015 (Contd..6) 42
Products under Development by Companies, H2 2015 (Contd..7) 43
Products under Development by Companies, H2 2015 (Contd..8) 44
Products under Investigation by Universities/Institutes, H2 2015 45
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 46
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H2 2015 47
Epilepsy - Pipeline by Advicenne Pharma, H2 2015 48
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015 49
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H2 2015 50
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2015 51
Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H2 2015 52
Epilepsy - Pipeline by Allergan Plc, H2 2015 53
Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2015 54
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015 55
Epilepsy - Pipeline by Astellas Pharma Inc., H2 2015 56
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2015 57
Epilepsy - Pipeline by BioCrea GmbH, H2 2015 58
Epilepsy - Pipeline by Bionomics Limited, H2 2015 59
Epilepsy - Pipeline by Biovista Inc., H2 2015 60
Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015 61
Epilepsy - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015 62
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 63
Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H2 2015 64
Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H2 2015 65
Epilepsy - Pipeline by D-Pharm Ltd., H2 2015 66
Epilepsy - Pipeline by Eisai Co., Ltd., H2 2015 67
Epilepsy - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 68
Epilepsy - Pipeline by Glialogix, Inc., H2 2015 69
Epilepsy - Pipeline by GW Pharmaceuticals Plc, H2 2015 70
Epilepsy - Pipeline by H. Lundbeck A/S, H2 2015 71
Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 72
Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2015 73
Epilepsy - Pipeline by Iproteos S.L., H2 2015 74
Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2015 75
Epilepsy - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 76
Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2015 77
Epilepsy - Pipeline by Lohocla Research Corporation, H2 2015 78
Epilepsy - Pipeline by Mapi Pharma Ltd., H2 2015 79
Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015 80
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015 81
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H2 2015 82
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2015 83
Epilepsy - Pipeline by Neuron Biopharma SA, H2 2015 84
Epilepsy - Pipeline by Novartis AG, H2 2015 85
Epilepsy - Pipeline by OPKO Health, Inc., H2 2015 86
Epilepsy - Pipeline by PharmatrophiX, Inc., H2 2015 87
Epilepsy - Pipeline by Promius Pharma, LLC, H2 2015 88
Epilepsy - Pipeline by Retrophin Inc., H2 2015 89
Epilepsy - Pipeline by Sage Therapeutics, H2 2015 90
Epilepsy - Pipeline by Saniona AB, H2 2015 91
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2015 92
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 93
Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 94
Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 95
Epilepsy - Pipeline by Turing Pharmaceuticals AG , H2 2015 96
Epilepsy - Pipeline by UCB S.A., H2 2015 97
Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015 98
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015 99
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2015 100
Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2015 101
Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H2 2015 102
Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H2 2015 103
Epilepsy - Pipeline by Zogenix, Inc., H2 2015 104
Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 105
Assessment by Monotherapy Products, H2 2015 106
Number of Products by Stage and Target, H2 2015 108
Number of Products by Stage and Mechanism of Action, H2 2015 113
Number of Products by Stage and Route of Administration, H2 2015 117
Number of Products by Stage and Molecule Type, H2 2015 119
Epilepsy Therapeutics - Recent Pipeline Updates, H2 2015 292
Epilepsy - Dormant Projects, H2 2015 354
Epilepsy - Dormant Projects (Contd..1), H2 2015 355
Epilepsy - Dormant Projects (Contd..2), H2 2015 356
Epilepsy - Dormant Projects (Contd..3), H2 2015 357
Epilepsy - Dormant Projects (Contd..4), H2 2015 358
Epilepsy - Dormant Projects (Contd..5), H2 2015 359
Epilepsy - Dormant Projects (Contd..6), H2 2015 360
Epilepsy - Discontinued Products, H2 2015 361
Epilepsy - Discontinued Products (Contd..1), H2 2015 362

List of Figures

Number of Products under Development for Epilepsy, H2 2015 22
Number of Products under Development for Epilepsy - Comparative Analysis, H2 2015 23
Number of Products under Development by Companies, H2 2015 24
Number of Products under Investigation by Universities/Institutes, H2 2015 30
Comparative Analysis by Late Stage Development, H2 2015 32
Comparative Analysis by Clinical Stage Development, H2 2015 33
Comparative Analysis by Early Stage Products, H2 2015 34
Assessment by Monotherapy Products, H2 2015 106
Number of Products by Top 10 Targets, H2 2015 107
Number of Products by Stage and Top 10 Targets, H2 2015 107
Number of Products by Top 10 Mechanism of Actions, H2 2015 112
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 112
Number of Products by Top 10 Routes of Administration, H2 2015 116
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 116
Number of Products by Molecule Types, H2 2015 118
Number of Products by Stage and Molecule Types, H2 2015 118

Published By: Global Markets Direct
Product Code: Global Markets Direct13487


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: